# Zoledronic Acid With Intermittent Hormonal Therapy in Patients With Prostate Cancer

> **NCT00226954** · PHASE2 · TERMINATED · sponsor: **Stanford University** · enrollment: 23 (actual)

## Conditions studied

- Urologic Neoplasms

## Interventions

- **DRUG:** zoledronic acid

## Key facts

- **NCT ID:** NCT00226954
- **Lead sponsor:** Stanford University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2003-03
- **Primary completion:** 2007-11
- **Final completion:** 2009-02
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2020-03-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00226954

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00226954, "Zoledronic Acid With Intermittent Hormonal Therapy in Patients With Prostate Cancer". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00226954. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*